ImmunityBio, Inc. 8-K

What Happened
On February 18, 2026, ImmunityBio, Inc. (IBRX) announced via press release (filed as Exhibit 99.1 to Form 8-K) that the European Commission has authorized ANKTIVA® in combination with BCG for the treatment of Non‑Muscle Invasive Bladder Cancer (Carcinoma in Situ). The authorization expands global access to the product to 33 countries.

Key Details

• Date filed: Form 8-K furnished on February 18, 2026.
• Product: ANKTIVA® (with BCG) authorized for Non‑Muscle Invasive Bladder Cancer — Carcinoma in Situ (CIS).
• Geographic impact: Authorization increases ANKTIVA’s availability to 33 countries in the European market.
• Disclosure: The company’s press release announcing the authorization is attached as Exhibit 99.1 to the 8-K.

Why It Matters
Regulatory authorization from the European Commission is a formal clearance that allows ImmunityBio to commercialize ANKTIVA with BCG across approved EU markets, potentially increasing the company’s addressable market in Europe. For investors, this is a material regulatory milestone that may affect future revenue opportunities, commercialization plans, and market access activities; subsequent updates investors should watch for include launch timing, pricing/reimbursement decisions, sales guidance, and any partner or distribution arrangements.